Live Sequent Scientific Share Price Chart
O H L VOL
Days Range
Data is not available currently. Please check back later.
Data is not available currently. Please check back later.
About Sequent Scientific
Incorporated in 2002, Sequent Scientific Limited is engaged in the business of providing a wide-ranging portfolio of animal health products, including Finished Dose Formulations and APIs, as well as analytical services to the pharmaceutical and life sciences industries. In 2003, the Hon'ble Bombay High Court approved the Scheme of Amalgamation of the company with P I Drugs and Pharmaceuticals Ltd. The company’s name was changed from PI Drugs and Pharmaceuticals Ltd to Sequent Scientific Ltd.
In 2013, Sequent Scientific Ltd announced a joint venture with Shasun Pharmaceuticals Ltd to establish a leading animal health company. The company continued its operational growth and achieved numerous milestones in 2014. During the year, the company announced the completion of the sale of the speciality chemicals division to Songwon Industrial Group. In addition, it acquired the business of Arvee Synthesis to provide impetus to the Human API business. In 2016, the company acquired a controlling stake in Indo Phyto Chemicals and entered into steroids and hormones. During the same year, it commenced production in the Vizag facility.
The company’s arm, Alivira, received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh in 2017. In 2020, the company announced the addition of a new state-of-the-art Animal Health R&D Centre in Mumbai. During the same year, it received EIR from the US FDA for its Analytical Laboratory in Bengaluru. In 2021, the company entered into the pet segment in Brazil. During the same year, the European Union Good Manufacturing Practices (EUGMP) received approval for its tablet dosage manufacturing line in Turkey.
Business Segments
- API: Under this segment, the company is engaged in the manufacturing of API. API business has 29 USVMFs + 18 CEPs (registered 5 VMFs and 3 CEPs in FY23) as of FY 2023. The company signed a long-term master supply arrangement with a global Top-10 animal health company. API has 30+ commercial APIs with 3 manufacturing facilities and 1 R&D center. The company made new investments in capacity expansion for leading customers and in expanding its own R&D capacity. The company launched 4 new API products in FY 2023.
- Formulation: The company has over 1000 final dosage formulations, 5 R&D centres devoted to the formulation industry, 6 manufacturing facilities in Europe, Turkey, Brazil, and India, and a marketing presence in more than 100 countries. In an effort to increase profitability, the company closed its manufacturing operations in its Germany factory in FY23 and relocated to a less expensive location. In FY23, their new Phyto line was introduced.
- Alivira Animal Health Limited: It is a wholly-owned subsidiary which was incorporated on September 30, 2013. It is the largest and 1st Global integrated animal health company specialising in the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).
- Laboratorios Karizoo S.A: This wholly-owned subsidiary was incorporated on May 09, 1983. Since its inception, the company has served the veterinary pharmaceutical sector.
Key Personnel
Mr. Rajaram Narayanan, Managing Director Mr Narayanan has over 25 years of experience and possesses a strong track record of leading revenue and profitability growth throughout multiple industries, including pharmaceuticals. Prior to joining the company, he worked with Sanofi India Limited as the Managing Director and Country Chair for India. He led the strategic reorientation of Sanofi’s India business operations. Mr. Narayanan started his career at Hindustan Unilever Ltd., where he held various leadership roles in India and other Asian markets for over 18 years, building and managing many iconic consumer brands. He is a BE (Hons)-Electrical and Electronics graduate from Birla Institute of Technology and Science, Pilani, and an MBA from the Indian Institute of Foreign Trade, New Delhi. He has completed the Advanced Management Program at Harvard Business School, USA.Corporate Actions
The company has no history of bonus issues, stock splits and other corporate actions.Parent Organisation
MNC Associate
Managing Director
Kamal K Sharma
Founded
1985
NSE Symbol
SEQUENT
Community Discussion
A
AngelOne
10th July, 2024
0 Likes
0 Replies
A
AngelOne
10th July, 2024
Sequent Scientific Ltd-latest-market-updates-84167
0 Likes
0 Replies
Popular stocks
Sequent Scientific Ltd FAQs
What is the share price of Sequent Scientific Ltd (SEQUENT) shares?
Sequent Scientific Ltd (SEQUENT) share price as of October 7, 2024, on NSE is Rs 198.7 (NSE) and Rs 198.7 (BSE) on BSE.
Can I buy Sequent Scientific Ltd (SEQUENT) from Angel One?
Yes, You can buy Sequent Scientific Ltd (SEQUENT) shares by opening a Demat account with Angel One.
How do I buy Sequent Scientific Ltd (SEQUENT) from Angel One?
Sequent Scientific Ltd (SEQUENT) share can be bought through the following modes:
1. Direct investment: You can buy Sequent Scientific Ltd (SEQUENT) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Sequent Scientific Ltd (SEQUENT) shares.
1. Direct investment: You can buy Sequent Scientific Ltd (SEQUENT) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Sequent Scientific Ltd (SEQUENT) shares.
Open Free Demat Account!
Enjoy ₹0 Account Opening Charges
Join our 2 Cr+ happy customers
Related Blogs
View All
4.4 Cr+DOWNLOADS
Enjoy Zero Brokerage on Equity Delivery
Get the link to download the App
